Dapagliflozin Slows FSGS Progression
Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.
Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
Androgen deprivation therapy added to radiation therapy (RT) for unfavorable-risk prostate cancer is not associated with an increased risk for cardiovascular mortality compared with RT alone, even among patients with preexisting cardiovascular disease, a study found.
In a study comparing the effect of 9 oral nonsteroidal anti-inflammatory drugs on kidney function, ibuprofen conferred the lowest risk for incident eGFR less than 60 mL/min/1.73 m2 and an eGFR decline of 30% or greater.
Oral sodium bicarbonate therapy given to patients with chronic kidney disease increases urinary pH but also increases urinary citrate levels, which may mitigate the risk for calcium phosphate stone formation.
New study is the first to characterize pegloticase use in the dialysis population.
Lack of timely referrals to nephrologists contribute to racial and ethnic disparities in kidney disease care.
Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study
In a study, patients who experienced hyperkalemia while on a renin-angiotensin-aldosterone-system inhibitor had the lowest 1-year risk of recurrent hyperkalemia when the medication was discontinued.
Black men with metastatic hormone-sensitive prostate cancer may have better outcomes if they receive enzalutamide rather than bicalutamide in combination with androgen deprivation therapy, data from a phase 2 trial suggests.